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Abstract: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and hetero-
geneous class of neoplasms. While surgical resection is the mainstay of treatment, non-surgical 
therapies play a role in the setting of unresectable and metastatic disease. The goals of medical 
therapy are directed both at alleviating symptoms of peptide release and shrinking tumor 
mass. Biotherapies such as somatostatin analogs and interferon can decrease the secretion of 
peptides and inhibit their end-organ effects. A second objective for treatment of unresectable 
GEP-NETs is limiting tumor growth. Options for limiting tumor growth include somatostatin 
analogs, systemic chemotherapy, locoregional therapies, ionizing radiation, external beam 
radiation, and newer targeted agents. In particular, angiogenesis inhibitors, tyrosine kinase 
inhibitors, and mTOR inhibitors have shown early promising results. The rarity of these tumors, 
their resistance to standard chemotherapy, and the excellent performance status of most of these 
patients, make a strong argument for consideration of novel therapeutic trials.
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Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and 
  heterogeneous class of neoplasms. Common gastrointestinal sites of origin include 
the endocrine pancreas and argentaffin cells of the gut which give rise to carcinoid 
tumors. Incidence rates range from 1–5/100,000, and recent reports have suggested 
an increasing incidence at several sites.1 Most GEP-NETs are malignant yet grow 
slowly in comparison with their adenocarcinoma counterparts. Most are functionally 
inactive but some produce hormones which lead to the clinical syndromes associ-
ated with hormone excess. Neuroendocrine tumors may arise sporadically or be 
associated with multiple endocrine neoplasia (MEN). Specifically, 10% of pancreatic 
neuroendocrine tumors (NETs) are associated with MEN 1, an autosomal dominant 
predisposition to parathyroid, pituitary, and pancreatic NETs.
Historically, there has been much debate about the nomenclature and classification 
of GEP-NETs. The inconsistency in classification and nomenclature has been problem-
atic. One common classification of endocrine tumors is according to the embryologic 
site of origin (ie, foregut, midgut, and hindgut). However, tumors of the foregut, 
which include the respiratory system, stomach, duodenum, proximal jejunum, and 
pancreas, are not comparable in terms of behavior and response to therapy. The 1980 
World Health Organization (WHO) classification instead subdivided the endocrine 
  gastrointestinal tumors into enterochromaffin (EC) cell, gastrin (G) cell, and unspecified 
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clinical, molecular, and histopathological features and 
suggested that the most appropriate terms to describe such 
tumors should be “endocrine tumor” or “neuroendocrine 
tumor”.2 Specifically, this latest system recognizes the 
  biologic behavior according to location, degree of tumor dif-
ferentiation, and peptide secreted, thus incorporating many 
features of prior classification attempts.
The new WHO classification is intended to address the 
need for a clinically relevant classification system, and we 
will review the medical treatment of GEP-NETs in this con-
text. While surgical resection is the mainstay of treatment, 
non-surgical therapies play a role in the setting of unresect-
able and metastatic disease. The goals of medical therapy 
are directed both at alleviating symptoms of peptide release 
and shrinking tumor mass.
Mediating the effects of peptide 
release
Most functional tumors of the gastroenteropancreatic system 
arise in the pancreas and include insulinomas, gastrinomas, 
VIPomas, glucagonomas, and somatostatinomas. Other 
functional tumors include duodenal gastrin-producing 
tumors and carcinoid tumors which generally occur in 
the ileum or appendix. Hindgut tumors are always non-
  functional. Biotherapies such as somatostatin analogs can 
both decrease the secretion of such peptides and inhibit their 
end-organ effects.
Somatostatin analogs
Somatostatin analogs are the mainstay of symptom 
management for patients with functional GEP-NETs. 
Somatostatin is a naturally occurring polypeptide pro-
duced by paracrine cells that are scattered throughout the 
gastrointestinal tract. Somatostatin inhibits gastrointestinal 
endocrine and exocrine function including the release of 
insulin, gastrin, glucagon, gastric, and pancreatic secre-
tions. Somatostatin was first used to control symptoms 
caused by GEP-NETs in the 1970s.3,4 Somatostatin has a 
2-minute half-life and therefore required a cumbersome 
continuous infusion and caused rebound hypersecretion of 
hormones. These characteristics made somatostatin clini-
cally impractical. Since then, longer-acting somatostatin 
analogs have been developed which have facilitated out-
patient use and minimized rebound symptoms.
Octreotide was the first somatostatin analog intro-
duced for clinical use. It has a half-life of 2 hours, requir-
ing 2–3 daily injections, and is not associated with the 
rebound symptoms that plagued the use of somatostatin.   
A meta-analysis of 62 published studies was performed 
in 1999 and examined the relationship between the short-
acting octreotide dose and efficacy in terms of decreasing 
urinary 5-HIAA levels, flushing, and diarrhea.5 The analysis 
found that increasing doses of octreotide (100–1000 µg/day) 
were directly associated with decreasing 5-HIAA levels 
and symptom improvement. Individualized dose titration 
was emphasized.
A longer-acting octreotide formulation (octreotide 
acetate LAR [long-acting repeatable]) was developed in the 
mid 1990s. The slow microsphere drug release of the LAR 
preparation offers the convenience of monthly intramuscular 
dosing. Studies comparing the shorter-acting and longer-
  acting forms of octreotide have demonstrated equal efficacy 
in terms of symptom control, with symptomatic response 
rates of 60% to 72% across groups.6 Other studies have 
reported 65% to 100% response rates with octreotide LAR. 
Initiation of octreotide LAR often requires coverage with 
a short-acting formulation for 2–3 weeks until steady-state 
levels of LAR are achieved.
Lanreotide LA and lanreotide Autogel® are more 
  prolonged release formulations of octreotide. Lanreo-
tide LA is a single strength, slow-release microparticle, 
  administered intramuscularly every 14 days. Like octreo-
tide LAR, lanreotide LA usually requires coverage with 
the shorter-acting octreotide until steady state-levels are 
reached. The symptomatic response rates with lanreotide 
LA range from 45% to 90%.7 Studies evaluating lanreotide 
versus short-acting octreotide in terms of efficacy, patient 
acceptability, and tolerance have favored lanreotide.8 
Lanreotide Autogel is a newer formulation supplied as a 
prefilled syringe of viscous aqueous solution and is admin-
istered by deep subcutaneous injection every 28 days and is 
only available in Europe; studies in the US are ongoing to 
allow for FDA filing. There are no studies directly compar-
ing the various longer-acting formulations.
The longer-acting somatostatin analogs are gener-
ally preferred for chronic symptom management with   
GEP-NETs because of ease of administration. However, the 
short-acting octreotide formulation is still preferred prior 
to invasive procedures for prevention and management of 
carcinoid crisis.
Somatostatin analogs are well tolerated with only mild 
side effects. Side effects are generally transient and include 
nausea, abdominal cramps, flatulence, diarrhea, steator-
rhea, hyperglycemia, cholelithiasis, and local injection site 
  reactions. Tachyphylaxis may be seen when somatostatin 
analogs are used for more than 12 months.Clinical and Experimental Gastroenterology 2010:3 81
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Interferon as a single agent has also shown some apop-
totic and cytostatic activity against GEP-NETs. However, the 
studies on IFNα in treatment of GEP-NETs have had small 
sample sizes and have not been randomized. IFNα leads to 
partial response in 11% of patients and disease stabilization 
in a median of 35%, lasting 32 months.7,9
Systemic chemotherapy
Systemic chemotherapy for well-differentiated neuroendo-
crine tumors is relatively ineffective, with slightly higher 
response rates in pancreatic NETs than in carcinoid tumors. 
Poorly differentiated NETs, independent of their origin, 
behave much more aggressively but have better response rates 
to systemic chemotherapy, usually with a platinum-based 
regimen (eg, cisplatin and etoposide). This review, however, 
is limited to treatment of well differentiated NETs.
A variety of chemotherapy regimens have been tested 
for well-differentiated neuroendocrine tumors of the pan-
creas and include platinum analogs (cis or carbo), chloro-
zotocin, dacarbazine (and its oral analog temozolomide), 
doxorubicin, etoposide, streptozocin (STZ), and paclitaxel. 
Streptozocin was first studied as an antimicrobial agent and 
was subsequently seen to have antitumor activity and to cause 
hyperglycemia through degranulation of islet beta cells. These 
findings lead to the study of streptozocin in the treatment of 
pancreatic islet cell tumors in the late 1960s. Since that time, 
streptozocin has been studied in combination with other 
agents, most notably in the 1992 multicenter, randomized 
study by Moertel et al in which 105 patients with advanced 
islet cell carcinoma were randomized to receive one of three 
treatment regimens: STZ + 5FU, STZ + doxorubicin, or chlo-
rozotocin monotherapy.14 STZ + doxorubicin was superior 
in terms of tumor regression, progression-free survival, and 
overall survival. Benefits were offset by toxicities of that regi-
men which included nausea and vomiting, myelosuppression, 
and anthracycline-induced cardiomyopathy (see Table 1).
Dacarbazine monotherapy has also been studied in the 
treatment of well-differentiated GEP-NETs. Studies have 
demonstrated overall response rates between 30% and 40%, 
sustained for 3 to 24 months.15,16 The most common toxicities 
associated with this regimen were mild nausea and vomit-
ing. Overall, dacarbazine is better tolerated and is easier to 
administer when compared with STZ combinations, although 
in non-randomized comparisons STZ combinations appear 
to be slightly more effective.
Temozolomide, an oral alternative to dacarbazine with a 
similar mechanism of action, has recently been studied in com-
bination with thalidomide, a putative anti-angiogenesis agent. 
interferons
Interferons (IFNs) have been used alone or in combination 
with chemotherapy and somatostatin analogs, mainly in the 
treatment of the carcinoid subset of GEP-NETs. Analysis 
of pooled data from published studies indicates a median 
symptomatic response rate of 40% to 70% for use of IFN 
alone, lower than those reported for somatostatin analogs.9 
Another drawback of IFN therapy when compared with the 
well tolerated somatostatin analogs is the side effect profile. 
IFNs are commonly associated with flu-like symptoms, 
chronic fatigue, depression, thyroid dysfunction, mild 
hepatotoxicity, and cytopenias. Trials assessing the effective-
ness of combination therapy have been mixed in terms of 
  symptomatic response.7,10 The primary role for IFN therapy 
may be in somatostatin-refractory patients.
Decreasing tumor burden
A second objective of treatment for unresectable GEP-NETs 
is limiting tumor growth. Although most GEP-NETs are 
slow growing, primary tumors and metastases can lead to 
symptoms depending on their anatomic location.
Somatostatin analogs and interferon
Somatostatin, in addition to its ability to inhibit gastrointestinal 
endocrine and exocrine function, may have apoptotic and 
cytostatic effects. Non-randomized trials evaluating response 
to somatostatin analogs have shown partial responses rang-
ing from 0% to 38%, and stabilization of disease, ranging 
from 37% to 87%, lasting between 8.5 and 18 months.7,11,12 
The first randomized study of octreotide LAR was recently 
reported.13 In this study (known as PROMID), patients with 
well-differentiated metastatic midgut neuroendocrine tumors 
were randomized to intramuscularly administered octreotide 
LAR 30 mg monthly versus placebo (n = 42 vs 43). Median 
TTP was longer in the treatment arm (14.3 months versus 
6 months; HR 0.34, P  0.05) and stable disease was seen 
in 67% and 37% of patients treated with octreotide LAR 
and placebo, respectively. This trial appears to confirm the 
antiproliferative potential of somatostatin analogs in mid-
gut carcinoids. However, it neither recorded nor stratified 
patients by growth rate of disease prior to study entry. Since 
a proportion of newly diagnosed non-functioning carcinoid 
tumors can remain stable for years, it seems prudent to limit 
routine use of somatostatin analogs to those patients who 
have documented growth of their disease. Additionally, these 
data cannot be extrapolated for routine use in non-midgut 
tumors until confirmatory studies at these disease sites are 
performed.Clinical and Experimental Gastroenterology 2010:3 82
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In that study of 29 patients with well-differentiated NETs, a 
25% radiologic response rate and a 40% biochemical response 
rate was observed.17 One of 14 patients with carcinoid 
responded while 5 of 11 patients with pancreatic NETs 
had radiographic responses. This once again confirms the 
observation that well-differentiated neuroendocrine tumors of 
the stomach, small and large intestine (ie, carcinoid tumors) 
are generally less responsive to systemic chemotherapy. 
Because temozolomide cytotoxicity is mediated by DNA 
alkylation and the DNA repair enzyme, methylguanine 
methyl transferase (MGMT) is responsible for repair of such 
adducts, tumors deficient in MGMT might be more sensitive 
to temozolomide. In fact, when neuroendocrine tumors are 
assayed for MGMT activity, the clinical responses correlate 
with MGMT deficiency. Additionally, MGMT deficiency is 
more common in pancreatic neuroendocrine tumors than in 
carcinoid tumors.18
Other temozolomide combinations also appear promis-
ing. In preliminary data on pancreatic NETs, combination 
of temozolomide + capecitabine has had very encouraging 
response rates (70%) suggesting that this combination war-
rants further evaluation.19,20
Locoregional therapies
Hepatic metastases commonly occur in patients with GEP-
NETs and adversely affect overall prognosis and quality of 
life. Since the effectiveness of somatostatin analogs wanes 
over time, therapies directed at locoregional control of hepatic 
disease may be necessary to decrease symptoms associated 
with hormone excess. Surgery for hepatic metastases should 
be considered whenever the metastases are considered resect-
able and when there is no evidence of extrahepatic disease. 
Thermal ablation or cryoablation may be considered as an 
adjunct to surgery or in settings where extrahepatic disease or 
comorbidities might favor a less aggressive intervention.
Hepatic metastases from GEP-NETs have a preferential 
arterial blood supply compared with normal liver paren-
chyma, thus offering a selective advantage to intra-arterial 
therapies. Selective catheterization of the hepatic artery and 
embolization of vessels perfusing the tumor(s) can result 
in clinically significant responses. Embolization has been 
performed using fragments of absorbable gelatin sponge or 
polyvinyl alcohol particles. The latter was investigated in a 
small group of 22 patients who received a median number 
of four embolizations, resulting in a partial radiographic 
response in 60% of treated patients, also associated with 
symptom improvement and decrease in hormone levels.21
Transcatheter arterial chemoembolization also utilizes 
the preferential arterial perfusion to deliver an emulsion 
of cytotoxic drug with normal saline and iodized oil. This 
is followed by embolization with gelatin sponge 2–3 mm 
particles or microspheres which are placed distally in the 
distribution of the hepatic artery until a decrease in blood 
flow is observed.22 Chemoembolization is a reasonable first-
line treatment in patients with symptomatic or progressive 
liver metastases, especially in patients with no clinically 
significant extrahepatic disease and in those with systemic 
symptoms that are no longer responsive to somatostatin 
analogs. Transcatheter arterial chemoembolization has 
proven effective both in terms of symptom relief and tumor 
response rates. Symptom relief has been reported in 63% 
to 100% of patients treated. Additionally, objective tumor 
response rates of 33% to 80% have been confirmed in many 
series, independent of GEP-NET tumor type.23 However, 
no benefit in overall survival has even been demonstrated, 
and comparisons between trials are problematic because 
of differences in cytotoxic agents and chemoembolization 
intervals. Post-embolization side effects include nausea, 
vomiting, abdominal pain, fever, and elevated liver AST 
and ALT. Major complications are rare, but include renal 
Table 1 randomized clinical trials of chemotherapy in GEP-NETs
Regimen  Study design  Tumor type  n  RR (%)  TTP 
(mo)
OS 
(mo)
Reference 
Strep/5FU vs Strep/ 
Cytoxan
Phase iii Mixed carcinoid 
and pancreas
42
47
33
26
  – – Moertel46
Strep/5FU 
vs Doxorubicin
Phase iii Carcinoid only 104
91
23*
20
7.8
6.5
16
12
Engstrom47 
Strep/Dox vs  
Strep/5FU vs  
Chlorotozocin
Phase iii Pancreas only 36
33
33
69*
45
30
69*
45
30
26.4*
16.8
16.8
Moertel14
Strep/5FU vs Dox/ 
5FU
Phase iii  Mixed carcinoid 
and pancreas
88 
88
16 
15.9
5.3 
4.5
24.3* 
15.7
Sun48 
*P ≤ 0.05.
Abbreviations: Dox, doxorubicin; 5FU, 5-fluorouracil; n, number; OS, overall survival; RR, response rate; strep, streptozocin; TTP, time to progression.Clinical and Experimental Gastroenterology 2010:3 83
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failure, liver failure, and bleeding peptic ulcers (due to 
inadvertent perfusion through the gastroduodenal artery).
Ultrasound-guided percutaneous alcohol injection, used 
historically in the treatment of hepatocellular carcinoma, has 
also been studied as an ablative therapy for small liver metas-
tases from GEP-NETs. Alcohol causes coagulative necrosis 
followed by fibrosis and thrombosis of small vessels. Studies 
evaluating percutaneous alcohol injection for GEP-NETs 
have lacked good design and adequate patient numbers. This 
technique has therefore been abandoned for other interven-
tional ablative therapies.
Radiofrequency (RF) ablation and cryotherapy are other 
interventional techniques aimed at regional destruction of 
liver metastases either alone or in combination with surgery 
for limited disease. RF ablation works by converting RF 
waves into heat and is considered in patients with fewer than 
5 lesions and lesions less than 35 mm in size. Berber et al 
evaluated laparoscopic RF ablation and reported symptomatic 
response rates of 80% to 95%, radiographic response rates 
of 97%, and response duration of 6 to 24 months.24 Hepatic 
cryotherapy involves serial freezing/thawing of liver tumors 
by means of an intraoperative cryoprobe which leads to tumor 
necrosis. This technique is frequently used at the time of 
surgery and has demonstrated successful results in terms of 
symptom control and tumor responses.
Radioembolization with selective internal radiation 
microspheres has been used for years to treat patients with 
unresectable liver metastases from primary and secondary 
liver cancers. A recent study specifically evaluated this 
treatment in patients with neuroendocrine liver metastases. 
Symptomatic responses were observed in 18 of 32 (55%) 
at 3 months and 16 of 32 (50%) at 6 months. Radiographic 
responses were observed in 50% of patients and included 6 
complete responses and 11 partial responses. Median overall 
survival was 29.4 months.25
ionizing radiation
Somatostatin receptor scintigraphy has been used for the 
past 20 years to identify patients with somatostatin-positive 
disease and otherwise undetectable metastatic foci. This same 
principle has been applied using radiolabeled somatostatin 
analogs with therapeutic doses of the radioactive isotope. The 
most commonly used radionuclides are indium (111I), yttrium 
(90Y), and lutetium (177Lu) and are only available in Europe. 
A study in patients with GEP-NETs demonstrated clinical 
responses in 46% of patients at three months (complete 2%, 
partial 28%, and minor 16%) and stable disease in 36%; 
the minority had progressive disease (20%). Median time 
to progression was 40 months and median overall survival 
was 128 months. The bone marrow and kidneys are the most 
important dose-limiting organs in peptide receptor radionu-
clide therapy.26
External beam radiation
External beam radiation therapy is of limited value in gas-
troenteropancreatic NETs and its main use is in palliative 
Table 2 Selected clinical trials using targeted agents in GEP-NETs
Regimen 
 
Study design 
 
Tumor type 
 
n 
 
RR (%) 
 
PFS or  
TTP  
(mo)
One year 
survival (%) 
Reference 
 
Angiogenesis inhibitors            
Temozolamide +  
thalidomide
Phase ii,  
single arm
Mixed carcinoid, 
pancreas and 
pheochromocytoma
29 45 (p)
7 (c)
13.5 79 Kulke17
Bev/Oct vs  
iFNα/Oct†
Phase ii,  
randomized
Carcinoid only 22
22
18  
0
— 93 Yao27
Tyrosine kinase inhibitors
Sunitinib Phase ii,  
Single arm
Mixed carcinoid and 
pancreas
109 17 (p)
2 (c)
7.7 (p)
10.2 (c)
81
83
Kulke32
Sunitinib vs  
placebo
Phase iii,  
randomized
Pancreatic only 75
79
– 11.1  
5.5
– raymond33
mTOR inhibitors
rAD001 vs  
rAD001+ Oct
Phase ii,  
two arm
Pancreatic only  115
45
7.8%
4.4%
9.3  
12.9 
50
90
Yao41
Abbreviations: Bev, bevacizumab; iFNα, interferon alpha; Oct, octreotide; C, carcinoid; P, pancreas; PFS, progression-free survival; rr, response rate; TTP, time to progression.
Note: †crossover allowed at 18 weeks.Clinical and Experimental Gastroenterology 2010:3 84
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therapy of the rare bone and brain metastases associated 
with this disease. Response rates of larger masses are low 
and anecdotal. Although efficacy data are lacking, its use 
may be reasonable in settings where resection of primary 
disease leaves positive margins such as in pancreatic or rectal 
neuroendocrine primaries. Stereotactic radiosurgery is being 
explored as an ablative technique for limited liver lesions on 
an experimental basis at our institution.
Targeted agents in clinical trials
Angiogenesis inhibitors
A trial of temozolomide and thalidomide, a putative first 
generation angiogenesis inhibitor, was discussed in the 
systemic chemotherapy section above.17 Bevacizumab, a 
monoclonal antibody that binds to vasculoendothelial growth 
factor (VEGF-A), is a more potent angiogenesis inhibitor and 
has demonstrated some encouraging early data in carcinoid 
tumors (see Table 2). In a study of 44 patients on octreotide 
and randomly assigned to either interferon or bevacizumab, 
a significant prolongation in progression-free survival was 
noted, favoring the bevacizumab arm (95% versus 68%).27 
This study was then designed to allow all patients to receive 
all three drugs (octreotide, bevacizumab, and interferon) 
after 18 weeks on study. This triplet biologic therapy resulted 
in a biochemical response rate of 46% with the majority of 
radiographic tumor responses occurring in the arm in which 
bevacizumab was administered first. Median progression-free 
survival by initial treatment assignment was not significant. 
Another study evaluating temozolomide and bevacizumab for 
advanced NETs showed a partial response rate of 14%, stable 
disease in 79%, with biochemical response in 36% (decrease 
in chromogranin A).28 Other trials utilizing bevacizumab, 
oxaliplatin, and a fluoropyrimidine are ongoing and have 
shown promising preliminary results.29,30
Data demonstrating marked reduction in perfusion 
of tumors after administration of angiogenesis inhibitors 
(see Figure 1) may provide a valuable surrogate marker of 
response in a disease for which radiographic responses are 
rare and the slow growth rate of most of these tumors makes 
assessment of progression-free survival problematic.31
Tyrosine kinase inhibitors
Oral multitargeted tyrosine kinase inhibitors (TKI) are being 
studied as monotherapies. In a phase II single-arm study, 
sunitinib (50 mg/day, 4 weeks on, 2 weeks off) showed an 
overall response rate of 17% in patients with pancreatic 
NETs and 2.4% in patients with carcinoid tumors. Median 
time to progression was 7.7 months versus 10.2 months in 
pancreatic NET and carcinoid tumor patients, respectively. 
The treatment was tolerated well with minimal side effects.32 
Figure 1 response to bevacizumab, capecitabine, and oxaliplatin.
On left are two cuts demonstrating the characteristic appearance of enhancing liver lesions (note that aorta is bright white signifying arterial phase scan) in a patient with a 
pancreatic neuroendocrine tumor. On right are corresponding cuts after 2 cycles (6 weeks) of bevacizumab, capecitabine, and oxaliplatin demonstrating marked decrease in 
vascularity of lesions.Clinical and Experimental Gastroenterology 2010:3 85
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A recent phase III trial of sunitinib in patients with metastatic 
pancreatic NETs was conducted in Europe. Patients were ran-
domized to receive either sunitinib (37.5 mg/day continuous 
daily dosing) or placebo. Progression-free survival increased 
from 5.5 months in the placebo group to 11.1 months in the 
sunitinib group (P  0.001). The study was discontinued 
prematurely by a data safety monitoring committee because 
of benefit observed in the sunitinib arm. Patients in the pla-
cebo arm were allowed to cross over.33
Sorafenib, a TKI primarily of VEGFR2 and PDGFR-β, 
has shown some modest activity in metastatic GEP-NETs. In 
a Phase II study by Hobday,34 the combined partial response + 
minor response rate was 17% for carcinoid tumor patients 
and 32% for pancreatic NET patients. Six-month progres-
sion-free survival was higher in the pancreatic group. Grade 
3–4 toxicity occurred in 43% of patients. Phase III trial of 
sorafenib versus placebo is underway.
Other TKIs have been evaluated, including vatalanib, a 
small molecule inhibitor primarily of VEGFR2 and PDGFR-β, 
which has shown some antiproliferative activity.35,36 Gefitinib, 
a small molecule inhibitor of the EGFR tyrosine kinase, has 
also been studied and showed good tolerability and prolonged 
disease stabilization in patients with progressive metastatic 
NETs.37 However, imatinib, a TKI of ABL, PDGFR and c-kit, 
was studied in a small Phase II study and showed significant 
toxicity without meaningful clinical activity.38
Other biologic agents
Another promising class of agents is the inhibitors of mTOR 
(mammalian targets of rapamycin). Temsirolimus has dem-
onstrated single agent activity and, more recently, everolimus 
has shown promising activity in combination with octreo-
tide.39–41 Phase III studies with everolimus are ongoing.
Other novel agents evaluated in recent clinical trials include 
bortezomib (a proteasome inhibitor),42 atiprimod (a novel pro-
apoptotic and antiangiogenic drug),43 AMG 479 (fully human 
monoclonal Ab antagonist of IGF-1R),44 and lithium carbonate 
(an inhibitor of glycogen synthase kinase-3β).45
Conclusion
Gastroenteropancreatic neuroendocrine tumors are biologi-
cally diverse, characteristically hypervascular, and clinically 
quite often indolent in growth rate. The rarity of these 
tumors, their resistance to standard chemotherapy, and the 
excellent performance status of most of these patients, make 
a strong argument for consideration of novel therapeutic 
trials at tertiary care centers that specialize in this disease. 
Better understanding of the biology of the disease and 
application of newly available less toxic drug combinations 
is reasonable cause for optimism in offering these patients 
longer quality-filled life expectancies.
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